October 27, 2015 Many sunscreens do not protect consumers as promised, report finds Sun worshippers, beware: Not all are sunscreen lotions and sprays are created equal.
October 27, 2015 New drugs treat advanced stages of a common skin cancer The most commonly-occurring cancer in the U.S. is basal-cell carcinoma, a type of skin cancer that is often treated with surgery or other procedures, and rarely fatal.
October 27, 2015 Learning the ABCs of skin cancer could save your life Melanoma can develop anywhere on your body, and while identifying it should be left to medical professionals, remembering your ABCs can help you detect a problem
October 27, 2015 UV exposure may cause drug-like addiction Given the numerous warnings linking sun exposure with skin cancer, why do so many people still worship the sunshine?
October 27, 2015 Why the FDA needs to approve new sunscreens for Americans New research continues to better define the risks of sunburn and sun exposure.
October 27, 2015 Fear of premature aging may encourage teens to use sunscreen Teenagers felt more compelled to apply sunscreen if they saw in a video that it could protect their skin from premature aging than if they saw that it could protect against cancer, a new study shows.
October 27, 2015 Vulnerable populations often miss cancer warning signs Some of society’s most vulnerable citizens are also most likely to overlook cancer warning signs, a new U.K. study suggests.
October 27, 2015 Deadlier skin cancer lurks outside of moles Out of the 74,000 people expected to be diagnosed with melanoma this year, almost 10,000 will die, the National Cancer Institute estimates.
October 27, 2015 Daily coffee may protect against melanoma, study says Those daily cups of coffee may do more than just provide energy, they may be protective against the most common type of melanoma, says a new study from the National Cancer Institute at the National Institutes of Health (NIH).
October 27, 2015 Merck says melanoma drug meets goal; study halted Merck & Co Inc said on Tuesday that it would stop a large study of its Keytruda melanoma treatment early because an independent monitoring committee determined the drug succeeded in its goal of prolonging survival in previously untreated patients at advanced stage of the disease.
